Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -49.72% is 24% below its 5-year average of -40.04%, around the middle of its 5-year range (-82.69%–0.04%).
75.78% below its 12-month average of -28.29%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.00%.
RETURN ON ASSETS (ROA)
-49.72%
RETURN ON ASSETS (ROA) AVG TTM
-28.29%
RETURN ON ASSETS (ROA) AVG 3Y
-39.08%
RETURN ON ASSETS (ROA) AVG 5Y
-40.04%
RETURN ON ASSETS (ROA) AVG 10Y
-50.42%
RETURN ON ASSETS (ROA) AVG 15Y
-47.60%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-75.78%
CURRENT VS 3Y AVG
-27.23%
CURRENT VS 5Y AVG
-24.19%
CURRENT VS 10Y AVG
+1.40%
CURRENT VS 15Y AVG
-4.46%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-29.12%
median of 605 covered companies
CURRENT VS SECTOR MEDIAN
-70.74%
vs the sector median at left
Lipocine Inc.
Market Cap
$17.15M
Return on Assets (ROA)
-49.72%
TTM Avg
-28.29%
3Y Avg
-39.08%
5Y Avg
-40.04%
Market Cap
$17.09M
Return on Assets (ROA)
-59.70%
TTM Avg
-56.25%
3Y Avg
-61.89%
5Y Avg
-61.99%
Market Cap
$16.75M
Return on Assets (ROA)
-67.58%
TTM Avg
-90.98%
3Y Avg
-83.38%
5Y Avg
-70.12%
Market Cap
$16.85M
Return on Assets (ROA)
-116.60%
TTM Avg
-66.28%
3Y Avg
-71.56%
5Y Avg
-63.10%
Market Cap
$15.88M
Return on Assets (ROA)
-154.34%
TTM Avg
-227.23%
3Y Avg
-240.86%
5Y Avg
-184.63%
Market Cap
$15.91M
Return on Assets (ROA)
-38.41%
TTM Avg
-84.87%
3Y Avg
-95.12%
5Y Avg
-75.66%
Market Cap
$15.44M
Return on Assets (ROA)
-213.77%
TTM Avg
-110.51%
3Y Avg
-93.41%
5Y Avg
-68.22%
Market Cap
$18.82M
Return on Assets (ROA)
-188.98%
TTM Avg
-90.06%
3Y Avg
-67.42%
5Y Avg
-51.71%
Market Cap
$18.70M
Return on Assets (ROA)
-64.55%
TTM Avg
-0.45%
3Y Avg
-55.72%
5Y Avg
-45.67%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Lipocine Inc. (LPCN) | $17.15M | -49.72% | -28.29% | -39.08% | -40.04% |
| Marker Therapeutics, Inc. (MRKR)vs › | $17.09M | -59.70% | -56.25% | -61.89% | -61.99% |
| Bionano Genomics, Inc. (BNGO)vs › | $16.75M | -67.58% | -90.98% | -83.38% | -70.12% |
| Dyadic International, Inc. (DYAI)vs › | $16.85M | -116.60% | -66.28% | -71.56% | -63.10% |
| BioCardia, Inc. (BCDA)vs › | $15.88M | -154.34% | -227.23% | -240.86% | -184.63% |
| Allarity Therapeutics, Inc. (ALLR)vs › | $15.91M | -38.41% | -84.87% | -95.12% | -75.66% |
| Cocrystal Pharma, Inc. (COCP)vs › | $15.44M | -213.77% | -110.51% | -93.41% | -68.22% |
| NextCure, Inc. (NXTC)vs › | $18.82M | -188.98% | -90.06% | -67.42% | -51.71% |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.70M | -64.55% | -0.45% | -55.72% | -45.67% |
| Pasithea Therapeutics Corp. (KTTA)vs › | $15.04M | -41.18% | -60.23% | -53.11% | -40.22% |
ROA
-49.7%
ROE
-54.5%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -56.61% |
| 2024-12-31 | 0.04% |
| 2023-12-31 | -71.09% |
| 2022-12-31 | -28.66% |
| 2021-12-31 | -1.21% |
| 2020-12-31 | -82.69% |
| 2019-12-31 | -66.17% |
| 2018-12-31 | -55.92% |
| 2017-12-31 | -82.85% |
| 2016-12-31 | -69.38% |
| 2015-12-31 | -40.13% |
| 2014-12-31 | -72.78% |
| 2013-12-31 | -22.97% |
| 2012-12-31 | 658872.79% |
| 2011-12-31 | -15.91% |
